Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2013 Annual Meeting
Second-Line Rituximab Maintenance for Follicular Lymphoma Cost-Effective
By
Caroline Helwick
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Dutch investigators found that rituximab (Rituxan) maintenance in the second-line treatment of patients with follicular lymphoma (FL) was cost-effective, as reported at the 2012 American Society of Hematology meeting.
Read Article
Ruxolitinib Treatment Reduces Myelofibrosis Symptoms, Spleen Size
By
Wayne Kuznar
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Ruxolitinib (Jakafi) alleviates symptoms such as fever, headache, weight loss, and fatigue, and reduces spleen size in patients with myelofibrosis.
Read Article
Infection Poses Lethal Risk Early in Patients with Multiple Myeloma
By
Charles Bankhead
ASH 2013 Annual Meeting
February 2013, Vol 4, No 2
Atlanta, GA—Many patients with multiple myeloma succumb to infection before they have a chance to benefit from cancer therapy, according to a new study from Sweden.
Read Article
Marker Helps Identify Most Aggressive Metastasized Breast Tumors
By
Rosemary Frei, MSc
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Boston, MA—Researchers believe they are closing in on a better way to identify breast cancers that are particularly dangerous and therefore require more aggressive therapy.
Read Article
Rivaroxaban More Cost-Effective than Warfarin in the Prevention of Recurrent VTE
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
For the prevention of recurrent venous thromboembolism (VTE), rivaroxaban (Xarelto) appears to be more cost-effective than warfarin (Coumadin), an independent analysis undertaken by the University of Pittsburgh School of Medicine showed.
Read Article
New Data Demonstrate Overall Survival Benefit with Pomalidomide in Advanced Myeloma
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—Support for the oral immunomodulatory agent pomalidomide for the treatment of multiple myeloma took a giant step forward when new data from the phase 3 MM-003 trial showed a survival advantage in patients with advanced disease.
Read Article
Oprozomib Shows Promise in Hematologic Malignancies
By
Lynne Lederman, PhD, Medical Writer
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—Promising preliminary results for oprozomib (ONX 0912), an orally available structural analogue of carfilzomib (Kyprolis), were presented at the 2012 American Society of Hematology meeting.
Read Article
Oral Proteasome Inhibitor MLN9708 a News Maker at ASH 2012
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—MLN9708, an investigational oral proteasome inhibitor, produced impressive results in a phase 1/2 clinical trial of treatment-naïve patients with multiple myeloma that was featured in a press briefing at the 2012 American Society of Hematology (ASH) meeting.
Read Article
Rasburicase Cost-Effective for Tumor Lysis Syndrome
By
Caroline Helwick
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
A study using real-world data for patients with tumor lysis syndrome (TLS) showed that treatment with rasburicase (Elitek) was associated with significantly greater reductions in uric acid, length of hospital stay, and total hospitalization costs per patient compared with allopurinol (Zyloprim).
Read Article
Ibrutinib: It’s Not Just for Leukemia
By
Audrey Andrews
ASH 2013 Annual Meeting
January 2013, Vol 4, No 1
Atlanta, GA—The investigational agent ibrutinib, which is making news in the treatment of patients with leukemia, demonstrated “unprecedented” single-agent activity in patients with relapsed or refractory mantle-cell lymphoma (MCL), according to the lead author of an international phase 2 study that was reported at the 2012 American Society of Hematology meeting.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma